Clinical trials: Coronavirus Infections
Corona Virus Infection, Covid19
Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
A preparation of CimertrA, comprising Artemisinin, Curcumin, and Boswellia, and Vitamin C in a nanoparticular formulation, is proposed as a treatment for the disease associated with the novel coronavirus SARS-CoV-2.
- Conditions
- Corona Virus Infection, Covid19, SARS-CoV Infection
- Trial name
- CimetrA (NCT04802382)
- Testing
- Confirm SARS-CoV-2 infection, Physical Examination, Vital Signs
- Where
- 2 sites in Israel
- Volunteers
- 252 people
- Sponsor
- MGC Pharmaceuticals d.o.o
Sars-CoV-2 Infection
AIDI - Research & Development of a Multisensor-Based Machine Learning Technology for Real-Time Automated Detection of COVID-19 Decompensation
The AIDI study has to phases. It's purpose is to capture vital signs using a non-invasive, hand-held, home monitoring device (MouthLab Device) from individuals with COVID-19 or who test positive for SARS-CoV-2 (Phase I) and use…
- Trial name
- AIDI (NCT05220306)
- Testing
- Monitoring of vital signs
- Where
- United States
- Sponsor
- AIDAR Health, Inc.
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Post Acute COVID-19 Syndrome
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue.
- Trial name
- AIDA (NCT05483829)
- Testing
- Adhera® Fatigue for Long COVID program
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Adhera Health, Inc.
COVID-19
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis
- Trial name
- SAIVE (NCT05305560)
- Testing
- Ivermectin Tablets
- Where
- Bulgaria
- Volunteers
- 400 people
- Sponsor
- MedinCell S.A
COVID-19, Coronavirus
Respiratory Decompensation and Model for the Triage of COVID-19 Patients
The purpose of this study is to prospectively evaluate a machine learning algorithm for the prediction of outcomes in COVID-19 patients.
- Conditions
- COVID-19, Coronavirus, Mortality, Mechanical Ventilation
- Trial name
- READY (NCT04390516)
- Testing
- COViage
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Dascena
COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Trial name
- NCT05689203
- Testing
- QLS1128
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
COVID-19
Detection of COVID-19 Subjects Using DiaNose Exhalation Test
The study aim is to collect and analyze data of potential Volatile Organic Compounds (VOCs) that could be used for discriminating between patients with and without COVID-19 or with high-risk for COVID-19 by DiaNose breath test.
- Trial name
- NCT04476927
- Testing
- DiaNose
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanose Medical Ltd.
COVID-19
Study of HS-10517 in Chinese Adult Participants
A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.
- Trial name
- NCT05779579
- Testing
- HS-10517 Dose 1, HS-10517 Dose 2, HS-10517 Dose 3
- Where
- China
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
Epidemiology of Thrombotic Thrombocytopenia Syndrome in Integrated Health-care Database in England
Background/Rationale: A rare syndrome of thrombosis associated with low platelets has been reported in a few cases of recent exposure to COVID-19 vaccine.
- Trial name
- NCT05222750
- Testing
- Pre-COVID-19, COVID-19, COVID-19 vaccination roll-out
- Where
- United Kingdom
- Volunteers
- 41,200,246 people
- Sponsor
- AstraZeneca
SARS-CoV-2 Infection
A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the…
- Trial name
- NCT04487574
- Testing
- XC221
- Where
- 5 sites in Russia
- Volunteers
- 118 people
- Sponsor
- RSV Therapeutics LLC
COVID-19
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention
The purpose of the study is to assess safety and immunogenicity of heterologous booster vaccine containing combination of AZD1222 and rAd26-S (one of components of Gam-COVID-Vac vaccine) in adult subjects aged ≥ 18 years old to…
- Trial name
- NCT04686773
- Testing
- AZD1222, rAd26-S
- Where
- Azerbaijan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
SARS-CoV-2, Seasonal Influenza
A Study of Modified mRNA Vaccines in Healthy Adults
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Trial name
- NCT05397223
- Testing
- mRNA-1273, mRNA-1010, mRNA-1345
- Where
- 8 sites in United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using…
- Trial name
- NCT06919796
- Testing
- COMIRNATY®
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (3~17 years old) Research purpose:Main purpose:To evaluate the safety and tolerability of recombinant New Coronavirus vaccine (CHO cells) in…
- Trial name
- NCT04961359
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Coronavirus Infection, COVID-19
WGS Analysis of COVID-19 Positive Patients
We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.
- Trial name
- NCT04353401
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Vanda Pharmaceuticals
Coronavirus
Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Popular title: Clinical study of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells). Purpose of the study: Main objectives: To evaluate the immunogenicity and safety of Omicron BA.4/5-Delta…
- Trial name
- NCT05850507
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel coronavirus protein vaccine (CHO cells)
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill
This is a randomized, double blind, two arms, placebo controlled, clinical trial to study to evaluate the the safety and efficacy of Mycobacterium w in combination with standard of care versus placebo with standard of care for…
- Trial name
- NCT04358809
- Testing
- Suspension of heat killed (autoclaved) Mycobacterium w
- Where
- 4 sites in India
- Volunteers
- 480 people
- Sponsor
- Cadila Pharnmaceuticals
COVID-19
A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in male outpatients with mild to moderate COVID-19 disease
- Trial name
- NCT04869228
- Where
- Brazil
- Volunteers
- 380 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.